header image

Products & Therapies

The Octapharma mission, “for the safe and optimal use of human proteins”, has seen the successful development of a specialised portfolio of products. These products, derived from human plasma and human proteins, are catagorised into three therapeutic areas:

Octapharma develops and manufactures high-purity coagulation factor concentrates for patients with bleeding disorders.

Octapharma's immunotherapy portfolio comprises high-purity human immunoglobulin products for treating various immune-mediated diseases and deficiencies.

Octapharma's Critical Care portfolio comprises human plasma and protein products for treating critically ill or injured patients in intensive care and emergency settings.